Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.24B |
| Revenue (ttm) | 24.03M |
| Net Income (ttm) | -219.62M |
| Shares Out | 55.58M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | 2.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 686,731 |
| Open | 22.73 |
| Previous Close | 22.79 |
| Day's Range | 22.22 - 22.73 |
| 52-Week Range | 19.80 - 31.56 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 35.75 (+60.53%) |
| Earnings Date | Feb 22, 2024 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $35.75, which is an increase of 60.53% from the latest price.
News
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Marke...
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint –
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancem...
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease –
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported busi...
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios' Scientific Expertise and Capabilities in Rare Hematologic Diseases ...
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
– Study's Primary Efficacy Endpoint Achieved, with 46.2% of Patients in the 50 mg BID Mitapivat Arm and 50.0% of Patients in the 100 mg BID Mitapivat Arm Achieving a Hemoglobin Response, Compared to 3...
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...
Agios Appoints Catherine Owen to Board of Directors
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- A...
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND ® (mitapivat) on Hemoglobin, Hemolysis, ...
Agios Reports Business Highlights and First Quarter 2023 Financial Results
– On Track for PYRUKYND ® (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 202...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th...
Agios Appoints Jeffrey Capello to Board of Directors
– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular me...
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th...
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility –
Agios to Participate in March Investor Conferences
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th...
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
Red Blood Cell Advisory Council Unites Patients, Caregivers and Physicians Across Pyruvate Kinase (PK) Deficiency, Thalassemia and Sickle Cell Disease to Generate Cross-indication Solutions, Support a...
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND ® (mitapivat) in Sickle Cell Disease –
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare Diseases
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency –
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...